Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002437 · ClinicalTrials.gov registry record · Phase 2
The Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT00002437 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 48 participants.
The verdict
NCT00002437, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
To determine whether cidofovir (HPMPC) therapy administered by intravenous infusion can extend the time to progression of peripheral cytomegalovirus (CMV) retinitis in AIDS patients. To evaluate the safety and tolerance of HPMPC therapy when administered by intravenous infusion in AIDS patients with CMV retinitis that is not immediately sight-threatening. To evaluate the virologic effects of intravenous HPMPC therapy on CMV shedding in urine, blood, and/or semen. To evaluate the impact of HPMPC therapy on visual acuity.
Interventions
- DRUG Probenecid
- DRUG Cidofovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002437
The ClinicalTrials.gov registry entry for NCT00002437 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Probenecid is the first listed.
NCT00002437 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002437 about?
NCT00002437 is a clinical study titled "The Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS". To determine whether cidofovir (HPMPC) therapy administered by intravenous infusion can extend the time to progression of peripheral cytomegalovirus (CMV) retinitis in AIDS patients. To evaluate the safety and tolerance of HPMPC therapy when administered by intravenous infusion in AIDS patients with...
What is the current status of trial NCT00002437?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants.
What interventions are being tested in trial NCT00002437?
The interventions under investigation include: Probenecid (DRUG), Cidofovir (DRUG).
Who is sponsoring clinical trial NCT00002437?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.